NCT06754904View on ClinicalTrials.gov

Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node

NARecruitingINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2032

Conditions
Melanoma, Skin
Interventions
PROCEDURE

Omitting TLND

Omitting TLND in patients who achieve an MPR in the index node following neoadjuvant ipilimumab and nivolumab.

PROCEDURE

Index node procedure

Index node procedure

Trial Locations (1)

3015GD

RECRUITING

Erasmus MC, Rotterdam

All Listed Sponsors
lead

D.J. (Dirk) Grünhagen

OTHER